IRIS Accounts Production v25.2.0.378 10001725 director 1.3.24 28.2.25 28.2.25 1/10/2025 0 0 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh100017252024-02-29100017252025-02-28100017252024-03-012025-02-28100017252023-02-28100017252023-03-012024-02-29100017252024-02-2910001725ns15:EnglandWales2024-03-012025-02-2810001725ns14:PoundSterling2024-03-012025-02-2810001725ns10:Director12024-03-012025-02-2810001725ns10:PrivateLimitedCompanyLtd2024-03-012025-02-2810001725ns10:SmallEntities2024-03-012025-02-2810001725ns10:Audited2024-03-012025-02-2810001725ns10:SmallCompaniesRegimeForDirectorsReport2024-03-012025-02-2810001725ns10:SmallCompaniesRegimeForAccounts2024-03-012025-02-2810001725ns10:FullAccounts2024-03-012025-02-2810001725ns10:RegisteredOffice2024-03-012025-02-2810001725ns5:CurrentFinancialInstruments2025-02-2810001725ns5:CurrentFinancialInstruments2024-02-2910001725ns5:Non-currentFinancialInstruments2025-02-2810001725ns5:Non-currentFinancialInstruments2024-02-2910001725ns5:ShareCapital2025-02-2810001725ns5:ShareCapital2024-02-2910001725ns5:RetainedEarningsAccumulatedLosses2025-02-2810001725ns5:RetainedEarningsAccumulatedLosses2024-02-2910001725ns5:PlantMachinery2024-03-012025-02-2810001725ns5:PlantMachinery2024-02-2910001725ns5:PlantMachinery2025-02-2810001725ns5:WithinOneYearns5:CurrentFinancialInstruments2025-02-2810001725ns5:WithinOneYearns5:CurrentFinancialInstruments2024-02-29
REGISTERED NUMBER: 10001725 (England and Wales)















CAPITAL PHARMA LIMITED

Audited Financial Statements for the Year Ended 28 February 2025






CAPITAL PHARMA LIMITED (REGISTERED NUMBER: 10001725)






Contents of the Financial Statements
for the Year Ended 28 February 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


CAPITAL PHARMA LIMITED

Company Information
for the Year Ended 28 February 2025







DIRECTOR: R E Sobol





REGISTERED OFFICE: 10th Floor
60 Church Street
Birmingham
West Midlands
B3 2DJ





REGISTERED NUMBER: 10001725 (England and Wales)





AUDITORS: Michael Dufty Partnership Limited
Statutory Auditors
59-61 Charlotte Street
St Pauls Square
Birmingham
West Midlands
B3 1PX

CAPITAL PHARMA LIMITED (REGISTERED NUMBER: 10001725)

Balance Sheet
28 February 2025

2025 2024
Notes £    £   
CURRENT ASSETS
Debtors 5 1,000 1,017
Cash at bank 256 571
1,256 1,588
CREDITORS
Amounts falling due within one year 6 179,028 171,503
NET CURRENT LIABILITIES (177,772 ) (169,915 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(177,772

)

(169,915

)

CREDITORS
Amounts falling due after more than one
year

7

25,009

30,519
NET LIABILITIES (202,781 ) (200,434 )

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Retained earnings (203,781 ) (201,434 )
SHAREHOLDERS' FUNDS (202,781 ) (200,434 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 1 October 2025 and were signed by:





R E Sobol - Director


CAPITAL PHARMA LIMITED (REGISTERED NUMBER: 10001725)

Notes to the Financial Statements
for the Year Ended 28 February 2025

1. STATUTORY INFORMATION

Capital Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 20% on cost

Assets are stated at bought in cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Debtors and creditors receivable/payable within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account.

Going concern
These financial statements have been prepared on a going concern basis.

The company retains the continued support of group companies, including parent company Jarell Limited which is supported by the groups banking facilities. Therefore the directors believe a going concern basis is appropriate.

CAPITAL PHARMA LIMITED (REGISTERED NUMBER: 10001725)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2025

2. ACCOUNTING POLICIES - continued

Factoring arrangements
The company has entered into a confidential invoice discounting arrangement in order to assist with cash management and day to day working capital requirements. Debts approved by the factor company are assigned with recourse. Debtors are reflected gross within current assets, with the related factoring advance reflected gross within current liabilities

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2024 - NIL).

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 March 2024
and 28 February 2025 3,550
DEPRECIATION
At 1 March 2024
and 28 February 2025 3,550
NET BOOK VALUE
At 28 February 2025 -

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Other debtors 1,000 1,017

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Bank loans and overdrafts 5,511 5,374
Trade creditors 87 479
Amounts owed to group undertakings 170,415 162,414
Taxation and social security 190 181
Other creditors 2,825 3,055
179,028 171,503

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2025 2024
£    £   
Bank loans 25,009 30,519

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal - 7,628

CAPITAL PHARMA LIMITED (REGISTERED NUMBER: 10001725)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2025

8. SECURED DEBTS

The following secured debts are included within creditors:

2025 2024
£    £   
Bounce Back Loan 30,520 35,894

The factoring liability is secured on debts to which the arrangement relates and an all asset debenture. The funding is subject to an overall borrowing limit of £3,900,000. This is a shared facility with other group companies.

The bank loan has a fixed interest rate of 2.5% over a 10 year term ending May 2030. The loan is secured via a government guarantee.

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Arran Jones FCCA (Senior Statutory Auditor)
for and on behalf of Michael Dufty Partnership Limited

10. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is R E Sobol.

Mr Sobol is the ultimate controlling party by virtue of his majority shareholding in the parent company, Jarell Limited.